Professional Documents
Culture Documents
7management of Multidrug-Resis
7management of Multidrug-Resis
discussions, stats, and author profiles for this publication at: http://www.researchgate.net/publication/49697158
CITATIONS
READS
42
127
2 AUTHORS:
H. Simon Schaaf
Ben Marais
Stellenbosch University
SEE PROFILE
SEE PROFILE
EDUCATIONAL AIMS
To discuss the epidemiology of and mechanisms responsible for the emergence of drug resistant TB in children
To provide clear guidance on how best to diagnose and treat drug-resistant TB in children
To discuss ancillary treatment options and the management of HIV-infected children with drug-resistant TB
A R T I C L E I N F O
S U M M A R Y
Keywords:
multidrug-resistant
tuberculosis
children
XDR-TB
MDR-TB
treatment
WHO estimated that of 9.4 million cases of tuberculosis (TB) worldwide in 2008, 440,000 (3.6%) had
multidrug-resistant (MDR)-TB. Childhood TB is estimated at 10-15% of the total burden, but little is
known about the burden of MDR-TB in children. Children in close contact with MDR-TB cases are likely to
become infected with the same resistant strains and are vulnerable to develop disease. Although MDRTB is a microbiological diagnosis, children should be treated empirically according to the drug
susceptibility result of the likely source case, as often cultures cannot be obtained from the child. MDRTB treatment in children is guided by the same principles, using the same second-line drugs as in adults,
with careful monitoring for adverse effects. Co-infection with HIV poses particular challenges and
requires early initiation of antiretroviral therapy. Preventive therapy for high-risk MDR-TB contacts is
necessary, but no consensus guidance exists on how best to manage these cases. Pragmatic and effective
Infection control measures are essential to limit the spread of MDR-TB.
2010 Elsevier Ltd. All rights reserved.
32
[()TD$FIG]
Conrmed DR-TB
DST known
Conrmed DS-TB
No
Suspected DR-TB
Do culture/DST on childs
specimens if DS not conrmed
mainly if poor response to treatment
33
34
Treat the child according to the DST results from the likely
source case, unless M. tuberculosis culture and DST is
available from the child
Do second-line DST in all MDR-TB cases to exclude
resistance to the uoroquinolones and/or second-line
injectables, as this may call for additional drugs early in
therapy
Give at least 3 (only in early primary disease) or preferably
4 drugs to which the patient or adult source case is nave or
their isolates susceptible
A regimen should be build from different drug groups (see
table 1) taking into account drug resistance, possible
cross-resistance, adverse effects and previous use of drugs
Caregivers need counseling and support regarding adverse
effects, treatment duration and importance of adherence
at every follow-up visit.
Clinical, radiological and culture response to treatment
should be monitored. Monthly smear microscopy and/or
cultures should be done until conrmed negative on 3
consecutive occasions, thereafter 2-3 monthly follow-up
cultures can be done
Clinical monitoring for adverse effects should be done at
every visit. Special investigations should be guided by the
adverse effect prole of the drugs used
Table 1
Drug groups for MDR and XDR-TB treatment regimens [Adapted from reference 26]
Drug Group
Drug name
Ethambutol
Pyrazinamide
Streptomycin (1st-line)
Amikacin
Kanamycin
Capreomycin
Ooxacin
Levooxacin
Moxioxacin
Ethionamide (or prothionamide)
Cycloserine (or terizidone)
e
Para-aminosalisylic acid (PAS; 4gr sachets)
High-dose INH
f
Linezolid
Amoxicillin/clavulanate
Clarithromycin
g
Thioacetazone
Imipenem/cilastatin
Clofazimine
20-25
30-40
15-20
15-20
15-20
15-20
15-20
7.5-10
7.5-10
15-20
10-20
150
15-20
10-12 twice daily
15 amoxicillin 3 x daily
7.5-15 twice daily
3-4
(only IV)
3-5
2000
2000
1000
1000
1000
1000
800
750
400
1000
1000
12g
400
300 once/twice daily
a. DST could be unreliable use as additional drug if DST result susceptible or not done25
b. Choose one drug in each of these groups; amikacin preferred to kanamycin in children
c. Choose one or more of these drugs to make up total of 4 new drugs
d. Consider use of these drugs if insufcient drugs to build an acceptable regimen with previous groups. Each drug only considered as half a drug, therefore 2 drugs in this
group counts as one additional drug.
e. PAS is administered in acidic base (e.g. yoghurt or orange juice) for improved absorption
f. Linezolid dosage for TB is uncertain, but lower doses (300 mg twice daily or even 300 mg daily in adults) cause less adverse effects and still seem effective.33
g. Thioacetazone should NOT be used in HIV-infected patients
35
involvement, severe forms of extrapulmonary disease or disseminated (meningitis or miliary TB) disease, the same duration as in
adults apply.
HOW TO ENSURE TREATMENT ADHERENCE?
It is essential to ensure adequate adherence to treatment, since
treatment options are limited. Treatment of MDR/XDR-TB should
only be given as directly observed therapy by health care workers
or treatment supporters. Hospitalization for the rst 4-6 months of
treatment is often required to administer second-line injectable
agents, monitor for adverse effects and ensure adequate treatment
response.
Comprehensive and continuous counseling of the child and/or
parent/caregiver is essential to ensure that they understand the
seriousness of the situation and the justication of prolonged and
complicated treatment regimens. Socioeconomic evaluation and
support of the family is important. Teenagers need special
attention and in our own experience, adherence should be checked
with the person responsible for direct observation of treatment.
Adverse effects of second-line drugs are more frequent than in
rst-line drug treatment; fortunately, these adverse effects can
usually be managed without stopping drugs (see Table 2).34 Nonavailability of child-friendly drugs and dosages complicates
administration of drugs to children.
Hospital/clinic-based and community-based treatment models
provide comparable outcomes.7,35 Some children require initial
admission because of their clinical condition or social circumstances. In our experience hospitalization in a specialized unit
during the intensive phase allows for daily injections by experienced
nursing staff and better monitoring of adverse effects and repeat
cultures. The remainder of the treatment is usually given at primary
health care level. Community home-based directly observed
treatment of HIV-uninfected MDR-TB patients in Peru was shown
to be very effective.35 In both models expert health care teams
should be involved in the continued care of the children.
Table 2
Adverse effects of rst and second-line drugs used in the treatment of children with multidrug-and extensively drug-resistant tuberculosis
Drug
Adverse effects
How to monitor
Isoniazid
Hepatotoxicity
Rash
Peripheral neuropathy (rare)
Psychosis
Hepatotoxicity
Arthralgia
Rash
Optic neuritis (rare)
Pyrazinamide
Ethambutol
Second-line injectable drugs
Amikacin
Kanamycin
Capreomycin
Fluoroquinolones
Ooxacin
Levooxacin
Moxioxacin
Thioamides
Ethionamide
Prothionamide
Cycloserine
Terizidone
Para-aminosalisylic acid (PAS)
Linezolid
Gastro-intestinal disturbance
Insomnia
Arthralgia
Clinical observation
Jaundice serum alanine transferase and billirubin
Thyroid stimulating hormone and free T4 levels
Clinical observation
Clinical observation
Thyroid stimulating hormone levels and free T4
Full blood counts
Serum lactate level
Clinical observation
Clinical observation
36
Corticosteroids
ADJUNCTIVE THERAPIES
Surgery
Nutritional support
Malnutrition increases the risk of developing disease after M.
tuberculosis infection, and optimal nutrition is an important part of
treatment. Because the diagnosis and treatment of MDR-TB is often
delayed,7 nutritional status in these children may have deteriorated. Additionally TB is known to be a disease associated with
poor socioeconomical circumstances, and second-line drugs such
as ethionamide and PAS may have gastrointestinal adverse effects
including nausea and anorexia. For these reasons children with
MDR-TB usually require nutritional support.
Several anti-TB and antiretroviral drugs may cause adverse
neurological effects which could be associated with low levels of
pyridoxine (vitamin B6). Low levels of pyridoxine was found in a
large proportion of children hospitalized for TB and levels
remained low in many HIV-infected children despite receiving
daily recommended doses of pyridoxine.40 Therefore pyridoxine is
recommended in TB/HIV-co-infected children but also for MDR-TB
patients receiving high-dose isoniazid and/or cycloserine/terizidone.15,40 Recommended dosage is 1-2 mg/kg daily.41
14.
15.
16.
17.
18.
19.
22.
CONCLUSION
23.
20.
21.
24.
25.
26.
27.
28.
29.
References
30.
1. World Health Organization. Multidrug and extensively drug-resistant TB (M/
XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland. WHO/HTM/TB/2010.3.
2. Nelson LJ, Wells CD. Global epidemiology of childhood tuberculosis. Int J Tuberc
Lung Dis 2004;8:63647.
3. Schaaf HS, Moll AP, Dheda K. Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management
in adults and children. Clin Chest Med 2009;30:66783.
4. Schaaf HS, Marais BJ, Hesseling AC, Brittle W, Donald PR. Surveillance of
antituberculosis drug resistance amongst children from the Western Cape
Province of South Africa an upward trend. Am J Public Health 2009;
99:148690.
5. Rieder HL. Drug-resistant tuberculosis: issues in epidemiology and challenges
for public health. Tuberc Lung Dis 1993;75:3213.
6. Marais BJ, Victor TC, Hesseling AC, et al. Beijing and Haarlem genotypes are
over-represented among children with drug resistant tuberculosis in the Western Cape Province of South Africa. J Clin Microbiol 2006;44:353943.
7. Schaaf HS, Shean K, Donald PR. Culture-conrmed multidrug-resistant tuberculosis inchildren: diagnostic delay, clinical features, response to treatment and
outcome. Arch Dis Child 2003;88:110611.
8. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir
Dis 1965;92:687703.
9. Snider Jr DE, Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and
disease among contacts of tuberculosis cases with drug-resistant and drugsusceptible bacilli. Am Rev Respir Dis 1985;132:12532.
10. Schaaf HS, Van Rie A, Gie RP, et al. Transmission of multidrug resistant
tuberculosis. Pediatr Infect Dis J 2000;19:6959.
11. Escombe A, Oeser C, Gilman R, et al. Natural ventilation for the prevention of
airborne contagion. PLoS Med 2007;4:e68.
12. Kritski AL, Marques MJ, Rabahi MF, et al. Transmission of tuberculosis to close
contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care
Med 1996;153:3315.
13. Steiner P, Rao M, Mitchell M, Steiner M. Primary drug-resistant tuberculosis in
children: Correlation of drug-susceptibility patterns of matched patient and
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
37
38
42.
43.
44.
45.
46.
47. American Thoracic Society. Centers for Disease Control and Prevention and
Infectious Disease Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221
47.
48. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker CJ, Long
SS, McMilan JA, eds. Red Book: 2006 Report of the Committee on Infectious
Diseases. 27th Ed, Elk Grove Village, IL. American Academy of Pediatrics
2006:678704.
49. Marais BJ, Gie RP, Hesseling AC, Beyers N. Adult-type pulmonary tuberculosis in
children 10-14 years of age. Pediatr Infect Dis J 2005;24:7434.
50. Curtis AB, Ridzon R, Vogel R, et al. Extensive transmission of Mycobacterium
tuberculosis from a child. N Engl J Med 1999;341:14915.
51. Munoz FM, Ong LT, Seavy D, Medina D, Correa A, Starke JR. Tuberculosis among
adult visitors of children with suspected tuberculosis and employees at a
childrens hospital. Infect Control Hosp Epidemiol 2002;23:56872.